在不同的临床病理亚组中评估先进EGFR突变NSCLC的第一线治疗:系统性审查和网络元分析
Ting Mei1,2, Ting Wang1,2, Qinghua Zhou3,4
1Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, 610000, China.
BMC cancer
|November 14, 2025
概括
奥西默蒂尼布加化学疗法 (CT) 和阿米万塔马布加拉泽蒂尼布是治疗EGFR突变的高级非小细胞肺癌 (NSCLC) 的有效一线治疗方法. 治疗选择取决于个体患者的特征,以获得最佳的结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 先进的EGFR突变非小细胞肺癌 (NSCLC) 需要有效的第一线疗法.
- 根据特定患者的临床病理特征量身定制治疗对于优化治疗结果至关重要.
研究的目的:
- 为了确定最有效的第一线治疗方案,用于先进的EGFR突变NSCLC.
- 为了比较各种治疗方案,包括单独或与其他药物结合使用的EGFR-TKI.
主要方法:
- 进行了网络元分析 (NMA).
- 数据来源于截至2023年12月发表的37项随机对照试验 (RCT).
- 搜索包括EMBASE,科克兰图书馆,PubMed和科学网的数据库.
主要成果:
- 欧西默提尼布+CT在整体队列的无进展生存期 (PFS) 中显示出最大的益处.
- 阿米万他马布 + 拉泽提尼布在整体存活期 (OS) 中提供了最大的益处.
- 特定的疗法在不同的子组 (如亚洲人,老年人,性别,突变亚型) 中显示出优异的结果.
结论:
- 对EGFR突变NSCLC的第一线治疗选择应根据临床病理特征进行个性化.
- 奥西默蒂尼布+CT和阿米万塔马布+拉泽蒂尼布是主要的治疗选择.
- 该NMA提供了关于高级NSCLC个性化治疗策略的证据.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.5K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
